Welcome

I am delighted to welcome you to this website dedicated to the listing of EUROAPI, a leading player in Active Pharmaceutical Ingredients (APIs) and a subsidiary of the Sanofi Group.

EUROAPI develops, manufactures, markets and distributes APIs through its API Solutions business and CDMO (Contract Development and Manufacturing Organization) activity. With a diversified technology portfolio and a unique know-how for the production of differentiated APIs manufactured in Europe, EUROAPI is positioned as the world’s leading manufacturer of small molecules and the second largest manufacturer of APIs (including small molecules and large molecules such as peptides and oligonucleotides).

Thanks to its leading position in a large number of API categories and highly differentiated APIs, our Group has many key advantages in a growing 72 billion market: a large and diversified portfolio of around 200 APIs comprising niche products, high standards of quality and compliance, six manufacturing sites all located in Europe, an array of cutting-edge technologies covering a wide range of scientific modalities and a sales network that enables us to serve our customers in over 80 countries.

Subject to approval at the Sanofi 2022 Shareholders Meeting, the listing would allow us to reinforce our status as a leading player in the API market, expanding our technology platforms and our presence in the most complex and differentiated APIs. We believe that our broad CDMO offering to the most innovative pharmaceutical and biotech companies and the development of our product portfolio will be a major growth driver, and that the evolution of our business scope combined with our operational excellence should help improve our margins and cash generation. This strategic roadmap will be supported by ambitious environmental and social commitments to build sustainable performance.

The Covid-19 health crisis has highlighted a mounting shortage of essential medicines for patients and a strong dependence to the drug value chain of Asia, especially for APIs. The creation of a major player in the API market combined with this listing is also intended to give us greater visibility and thus contribute to securing high quality APIs manufacturing, developing and strengthening supply capacity for Europe and beyond.

Finally, although Sanofi is committed to remaining a long-term strategic partner for EUROAPI, our listing would give us the independence to pursue new business opportunities, with the French State, through the fund French Tech Souveraineté, as a long-term reference shareholder as it would hold 12% of EUROAPI’s capital.

EUROAPI will be able to rely on the expertise of approximately 3,350 employees and 530 long-standing customers, including most of the largest companies in the pharmaceutical industry, working together to develop, manufacture, market and distribute European medicines worldwide.

Karl Rotthier
Chief Executive Officer